{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Mitomycine : Questions médicales les plus fréquentes",
"headline": "Mitomycine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Mitomycine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-23",
"dateModified": "2025-02-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Mitomycine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Mitomycines",
"url": "https://questionsmedicales.fr/mesh/D008937",
"about": {
"@type": "MedicalCondition",
"name": "Mitomycines",
"code": {
"@type": "MedicalCode",
"code": "D008937",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.473.412.249"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Mitomycine",
"alternateName": "Mitomycin",
"code": {
"@type": "MedicalCode",
"code": "D016685",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Elise Champeil",
"url": "https://questionsmedicales.fr/author/Elise%20Champeil",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu."
}
},
{
"@type": "Person",
"name": "Owen Zacarias",
"url": "https://questionsmedicales.fr/author/Owen%20Zacarias",
"affiliation": {
"@type": "Organization",
"name": "Department of Sciences, John Jay College of Criminal Justice, New York, NY 10019, United States."
}
},
{
"@type": "Person",
"name": "Maggie Zheng",
"url": "https://questionsmedicales.fr/author/Maggie%20Zheng",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: maggie.zheng@jjay.cuny.edu."
}
},
{
"@type": "Person",
"name": "Timothy Snyder",
"url": "https://questionsmedicales.fr/author/Timothy%20Snyder",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: timothy.snyder@jjay.cuny.edu."
}
},
{
"@type": "Person",
"name": "Gloria Proni",
"url": "https://questionsmedicales.fr/author/Gloria%20Proni",
"affiliation": {
"@type": "Organization",
"name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: gproni@jjay.cuny.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Critical care management of patients with lymphatic conduction disorders.",
"datePublished": "2024-05-23",
"url": "https://questionsmedicales.fr/article/38796974",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.sempedsurg.2024.151423"
}
},
{
"@type": "ScholarlyArticle",
"name": "Bronchiectasis management in adults: state of the art and future directions.",
"datePublished": "2024-05-23",
"url": "https://questionsmedicales.fr/article/38782469",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1183/13993003.00518-2024"
}
},
{
"@type": "ScholarlyArticle",
"name": "AAPM&R consensus guidance on spasticity assessment and management.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38770827",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pmrj.13211"
}
},
{
"@type": "ScholarlyArticle",
"name": "Grouping strategies for assessing and managing persistent and mobile substances.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38784824",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12302-024-00919-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Managing extreme AI risks amid rapid progress.",
"datePublished": "2024-05-20",
"url": "https://questionsmedicales.fr/article/38768279",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/science.adn0117"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indoles",
"item": "https://questionsmedicales.fr/mesh/D007211"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolequinones",
"item": "https://questionsmedicales.fr/mesh/D045563"
},
{
"@type": "ListItem",
"position": 7,
"name": "Mitomycines",
"item": "https://questionsmedicales.fr/mesh/D008937"
},
{
"@type": "ListItem",
"position": 8,
"name": "Mitomycine",
"item": "https://questionsmedicales.fr/mesh/D016685"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Mitomycine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Mitomycine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Mitomycine",
"description": "Comment la mitomycine est-elle administrée ?\nQuels tests sont nécessaires avant traitement ?\nLa mitomycine est-elle utilisée pour tous les cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nY a-t-il des contre-indications au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Data+Management&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Mitomycine",
"description": "Quels sont les effets secondaires courants ?\nLa mitomycine cause-t-elle des douleurs ?\nQuels symptômes indiquent une réaction allergique ?\nPeut-elle affecter le système immunitaire ?\nQuels signes de toxicité doivent alerter ?",
"url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Data+Management&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Mitomycine",
"description": "Comment minimiser les effets secondaires ?\nDes vaccinations sont-elles nécessaires ?\nComment éviter les infections pendant le traitement ?\nY a-t-il des recommandations alimentaires ?\nComment gérer le stress pendant le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Data+Management&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Mitomycine",
"description": "La mitomycine est-elle utilisée seule ?\nQuelle est la durée du traitement ?\nComment surveiller l'efficacité du traitement ?\nQuels soins de soutien sont recommandés ?\nY a-t-il des interactions médicamenteuses ?",
"url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Data+Management&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Mitomycine",
"description": "Quelles sont les complications possibles ?\nLa mitomycine peut-elle causer des cancers secondaires ?\nComment gérer une toxicité sévère ?\nQuels tests pour surveiller les complications ?\nY a-t-il des effets à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Data+Management&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Mitomycine",
"description": "Qui est à risque d'effets secondaires ?\nLes antécédents de cancer augmentent-ils le risque ?\nLe tabagisme influence-t-il le traitement ?\nY a-t-il des facteurs génétiques à considérer ?\nL'âge influence-t-il la tolérance au traitement ?",
"url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Data+Management&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la mitomycine est-elle administrée ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La mitomycine est généralement administrée par injection intraveineuse ou intravésicale."
}
},
{
"@type": "Question",
"name": "Quels tests sont nécessaires avant traitement ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des examens d'imagerie sont souvent requis pour évaluer la santé du patient."
}
},
{
"@type": "Question",
"name": "La mitomycine est-elle utilisée pour tous les cancers ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, elle est principalement utilisée pour des cancers spécifiques comme le cancer de la vessie."
}
},
{
"@type": "Question",
"name": "Quels marqueurs tumoraux sont surveillés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs comme le CA 19-9 peuvent être surveillés selon le type de cancer traité."
}
},
{
"@type": "Question",
"name": "Y a-t-il des contre-indications au traitement ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies ou de maladies rénales peuvent être des contre-indications."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, et fatigue."
}
},
{
"@type": "Question",
"name": "La mitomycine cause-t-elle des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer des douleurs abdominales ou des douleurs au site d'injection."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des démangeaisons, éruptions cutanées ou difficultés respiratoires peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Peut-elle affecter le système immunitaire ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la mitomycine peut réduire les globules blancs, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quels signes de toxicité doivent alerter ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des saignements inhabituels ou des ecchymoses peuvent indiquer une toxicité."
}
},
{
"@type": "Question",
"name": "Comment minimiser les effets secondaires ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hydratation et des médicaments antiémétiques peuvent aider à réduire les effets secondaires."
}
},
{
"@type": "Question",
"name": "Des vaccinations sont-elles nécessaires ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement."
}
},
{
"@type": "Question",
"name": "Comment éviter les infections pendant le traitement ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter les foules et pratiquer une bonne hygiène peut aider à prévenir les infections."
}
},
{
"@type": "Question",
"name": "Y a-t-il des recommandations alimentaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et riche en nutriments est recommandée pour soutenir le traitement."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pendant le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de relaxation et le soutien psychologique peuvent aider à gérer le stress."
}
},
{
"@type": "Question",
"name": "La mitomycine est-elle utilisée seule ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut être utilisée seule ou en combinaison avec d'autres agents chimiothérapeutiques."
}
},
{
"@type": "Question",
"name": "Quelle est la durée du traitement ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée varie selon le type de cancer, mais elle est souvent administrée sur plusieurs cycles."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'efficacité du traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens d'imagerie et des tests sanguins réguliers sont utilisés pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels soins de soutien sont recommandés ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien comme la gestion de la douleur et des conseils nutritionnels sont recommandés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des interactions médicamenteuses ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la mitomycine peut interagir avec d'autres médicaments, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des infections, des saignements et des problèmes rénaux."
}
},
{
"@type": "Question",
"name": "La mitomycine peut-elle causer des cancers secondaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation de mitomycine peut augmenter le risque de cancers secondaires à long terme."
}
},
{
"@type": "Question",
"name": "Comment gérer une toxicité sévère ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une hospitalisation et un traitement symptomatique peuvent être nécessaires en cas de toxicité sévère."
}
},
{
"@type": "Question",
"name": "Quels tests pour surveiller les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins réguliers et des examens d'imagerie sont nécessaires pour surveiller les complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets à long terme peuvent inclure des problèmes pulmonaires ou rénaux, nécessitant un suivi."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets secondaires ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées et celles avec des antécédents médicaux complexes sont plus à risque."
}
},
{
"@type": "Question",
"name": "Les antécédents de cancer augmentent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de cancer peuvent augmenter le risque d'effets secondaires lors du traitement."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le traitement ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut affecter l'efficacité du traitement et augmenter les risques d'effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques à considérer ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines variations génétiques peuvent influencer la réponse au traitement par mitomycine."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la tolérance au traitement ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients plus âgés peuvent avoir une tolérance réduite aux effets de la mitomycine."
}
}
]
}
]
}
Lymphatic dysfunction in critical illness is complex. Primary complex lymphatic anomalies can lead to profound organ dysfunction, particularly respiratory failure and shock. Critical illness, the comp...
Formerly regarded as a rare disease, bronchiectasis is increasingly recognised. A renewed interest in this disease has led to significant progress in bronchiectasis research. Randomised clinical trial...
The American Academy of Physical Medicine and Rehabilitation (AAPM&R) conducted a comprehensive review in 2021 to identify opportunities for enhancing the care of adult and pediatric patients with spa...
To develop consensus-based practice recommendations to identify and address gaps in spasticity care....
The Spasticity TEP engaged in a 16-month virtual meeting process, focusing on formulating search terms, refining research questions, and conducting a structured evidence review. Evidence quality was a...
The TEP approved five recommendations for spasticity management and five best practices for assessment and management, with one recommendation unable to be graded due to evidence limitations. Best pra...
This consensus guidance provides clinicians with practical recommendations for spasticity assessment and management based on the best available evidence and expert opinion. Clinical judgment should be...
Persistent, mobile and toxic (PMT), or very persistent and very mobile (vPvM) substances are a wide class of chemicals that are recalcitrant to degradation, easily transported, and potentially harmful...
Substance grouping has helped global regulation of some highly hazardous chemicals, e.g., through the Montreal Protocol and the Stockholm Convention. This article explores the potential of grouping st...
Effective substance grouping can accelerate the assessment and management of PMT/vPvM substances, especially for substances that lack information. Advances to read-across methods and cheminformatics t...
Two surveys were conducted to assess the prevalence and risk factors of ovine caseous lymphadenitis (CL) and explore the association between its superficial and visceral forms in Sardi sheep in Settat...
To construct a structural model of family management for children with atopic dermatitis....
In this cross-sectional study, data were collected using a structured questionnaire. Participants included primary caregivers of children aged 2-12 years who had received a medical diagnosis of atopic...
Family functioning resilience, social support, and family coping had significant direct effects on family management. Illness severity, illness duration, and family life difficulty indirectly influenc...
The final model was suitable for predicting family management for children with atopic dermatitis. By confirming mediating effects, this study contributes to enhancing family management through nursin...
Nursing interventions targeting the alleviation of family management challenges and enhancement of family functioning resilience, social support, and family coping are pivotal for improving the well-b...
We include biodiversity impacts in forest management decision making by incorporating the countryside species area relationship model into the partial equilibrium model GLOBIOM-Forest. We tested three...
High-resolution computed tomography (HRCT) plays a pivotal role in the diagnosis and management of interstitial lung diseases (ILDs), particularly given the approval of antifibrotic agents for conditi...
Metal-organic frameworks (MOFs) hold great promise for diverse applications when combined with polymers. However, a persistent challenge lies in the susceptibility of exposed MOF pores to molecule and...